Affordable Access

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update

Authors
  • Smolen, Josef S;
  • Landewe, Robert BM;
  • Bijlsma, Johannes WJ;
  • Burmester, Gerd R;
  • Dougados, Maxime;
  • Kerschbaumer, Andreas;
  • McInnes, Iain B;
  • Sepriano, Alexandre;
  • van Vollenhoven, Ronald F;
  • de Wit, Maarten;
  • Aletaha, Daniel;
  • Aringer, Martin;
  • Askling, John;
  • Balsa, Alejandro;
  • Boers, Maarten;
  • den Broeder, Alfons A;
  • Buch, Maya H;
  • Buttgereit, Frank;
  • Caporali, Roberto;
  • Cardiel, Mario Humberto;
  • And 27 more
Publication Date
Jun 01, 2020
Source
Lirias
Keywords
License
Unknown
External links

Abstract

OBJECTIVES: To provide an update of the European League Against Rheumatism (EULAR) rheumatoid arthritis (RA) management recommendations to account for the most recent developments in the field. METHODS: An international task force considered new evidence supporting or contradicting previous recommendations and novel therapies and strategic insights based on two systematic literature searches on efficacy and safety of disease-modifying antirheumatic drugs (DMARDs) since the last update (2016) until 2019. A predefined voting process was applied, current levels of evidence and strengths of recommendation were assigned and participants ultimately voted independently on their level of agreement with each of the items. RESULTS: The task force agreed on 5 overarching principles and 12 recommendations concerning use of conventional synthetic (cs) DMARDs (methotrexate (MTX), leflunomide, sulfasalazine); glucocorticoids (GCs); biological (b) DMARDs (tumour necrosis factor inhibitors (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab), abatacept, rituximab, tocilizumab, sarilumab and biosimilar (bs) DMARDs) and targeted synthetic (ts) DMARDs (the Janus kinase (JAK) inhibitors tofacitinib, baricitinib, filgotinib, upadacitinib). Guidance on monotherapy, combination therapy, treatment strategies (treat-to-target) and tapering on sustained clinical remission is provided. Cost and sequencing of b/tsDMARDs are addressed. Initially, MTX plus GCs and upon insufficient response to this therapy within 3 to 6 months, stratification according to risk factors is recommended. With poor prognostic factors (presence of autoantibodies, high disease activity, early erosions or failure of two csDMARDs), any bDMARD or JAK inhibitor should be added to the csDMARD. If this fails, any other bDMARD (from another or the same class) or tsDMARD is recommended. On sustained remission, DMARDs may be tapered, but not be stopped. Levels of evidence and levels of agreement were mostly high. CONCLUSIONS: These updated EULAR recommendations provide consensus on the management of RA with respect to benefit, safety, preferences and cost. / status: published

Report this publication

Statistics

Seen <100 times